These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
323 related articles for article (PubMed ID: 31768009)
1. The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma. Tolomelli G; Mancuso K; Tacchetti P; Patriarca F; Galli M; Pantani L; Zannetti B; Motta MR; Rizzi S; Dan E; Sinigaglia B; Giudice V; Olmo A; Arpinati M; Chirumbolo G; Fanin R; Lewis RE; Paris L; Bonifazi F; Cavo M; Curti A; Lemoli RM Bone Marrow Transplant; 2020 May; 55(5):946-954. PubMed ID: 31768009 [TBL] [Abstract][Full Text] [Related]
2. Successful Mobilization of Autologous Hematopoietic Peripheral Blood Stem Cells after Salvage Chemotherapy in Patients with Low CD34 Blood Cell Counts. Holmberg LA; Linenberger M; Connelly-Smith L Transplant Cell Ther; 2022 Nov; 28(11):754-759. PubMed ID: 36002104 [TBL] [Abstract][Full Text] [Related]
3. A prospective, multicenter study on hematopoietic stemcell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents. Mina R; Petrucci MT; Bonello F; Bongarzoni V; Saccardi R; Bertuglia G; Mengarelli A; Spadaro A; Lisi C; Curci P; Lemoli RM; Ballanti S; Floris R; Cupelli L; Tosi P; Olivieri A; Rota-Scalabrini D; Cangialosi C; Nozzoli C; Anaclerico B; Fazio F; Bruno B; Mancuso K; Corradini P; Milone G; Boccadoro M Haematologica; 2024 May; 109(5):1525-1534. PubMed ID: 37981892 [TBL] [Abstract][Full Text] [Related]
4. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial. Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613 [TBL] [Abstract][Full Text] [Related]
5. Are we choosing mobilization regimens for autologous stem cell transplantation in multiple myeloma wisely: A single center comparison of GCSF+/-plerixafor vs cyclophosphamide/GCSF+/-plerixafor. Yang C; Dehghani M; Hopman W; Bhella S J Clin Apher; 2022 Aug; 37(4):348-353. PubMed ID: 35218068 [TBL] [Abstract][Full Text] [Related]
6. Phase I/II Study of Intravenous Plerixafor Added to a Mobilization Regimen of Granulocyte Colony-Stimulating Factor in Lymphoma Patients Undergoing Autologous Stem Cell Collection. Cashen AF; Rettig M; Gao F; Smith A; Abboud C; Stockerl-Goldstein K; Vij R; Uy G; Westervelt P; DiPersio J Biol Blood Marrow Transplant; 2017 Aug; 23(8):1282-1289. PubMed ID: 28476490 [TBL] [Abstract][Full Text] [Related]
7. The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by "on-demand" addition of plerixafor to granulocyte-colony-stimulating factor. Girbl T; Lunzer V; Greil R; Namberger K; Hartmann TN Transfusion; 2014 Sep; 54(9):2325-35. PubMed ID: 24673458 [TBL] [Abstract][Full Text] [Related]
8. Autologous peripheral blood stem cell mobilization and collection in patients with lymphoma and multiple myeloma: A single-center experience using the plerixa for pre-emptive approach. Alsaeed AS; Najib MJ; Al Amoudi SM; Elhemaidi IY; Absi AA; Al Ahmadi MD; Eldadah SK; Rajkhan WA; Khalil MM; Almohammadi MH Saudi Med J; 2022 Jun; 43(6):626-632. PubMed ID: 35675941 [TBL] [Abstract][Full Text] [Related]
9. Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma. Hartmann T; Hübel K; Monsef I; Engert A; Skoetz N Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD010615. PubMed ID: 26484982 [TBL] [Abstract][Full Text] [Related]
10. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma. Steinberg M; Silva M Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493 [TBL] [Abstract][Full Text] [Related]
11. A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: An Italian explorative cost Analysis. Laszlo D; Marcacci GP; Martino M; Radice D; Rabascio C; Lucchetti B; Magarò A; Caime A; Menna S; Lionetti MT; Bertolini F Transfus Apher Sci; 2020 Oct; 59(5):102819. PubMed ID: 32499108 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. Stewart DA; Smith C; MacFarland R; Calandra G Biol Blood Marrow Transplant; 2009 Jan; 15(1):39-46. PubMed ID: 19135941 [TBL] [Abstract][Full Text] [Related]
14. Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma. Avigan ZM; Arinsburg S; Pan D; Mark T; Fausel C; Bubalo J; Milkovich G; Moshier E; Fu W; Chari A; Richter J Bone Marrow Transplant; 2024 Oct; 59(10):1440-1448. PubMed ID: 39085373 [TBL] [Abstract][Full Text] [Related]
15. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program. Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037 [TBL] [Abstract][Full Text] [Related]
16. Plerixafor strategies for autologous hematopoietic cell transplant mobilization: A comparison of efficacy and cost. Chen KY; Bucci TG; Shaw JR; Alexander MD; Grgic T; Riches M; Ptachcinski JR Transfus Apher Sci; 2022 Apr; 61(2):103303. PubMed ID: 34801430 [TBL] [Abstract][Full Text] [Related]
17. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function. Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017 [TBL] [Abstract][Full Text] [Related]
18. CD34+ cell subclasses and lymphocyte subsets in blood grafts collected after various mobilization methods in myeloma patients. Varmavuo V; Mäntymaa P; Silvennoinen R; Nousiainen T; Kuittinen T; Jantunen E Transfusion; 2013 May; 53(5):1024-32. PubMed ID: 22897584 [TBL] [Abstract][Full Text] [Related]
19. Impact of Plerixafor Use at Different Peripheral Blood CD34 Shah EE; Young RP; Wong SW; Damon LE; Wolf JL; Shah ND; Leavitt AD; Loeffler P; Martin TG Biol Blood Marrow Transplant; 2020 May; 26(5):876-883. PubMed ID: 31785375 [TBL] [Abstract][Full Text] [Related]
20. Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial. Jagirdar N; Harvey RD; Nooka A; Flowers C; Kaufman J; Lonial S; Lechowicz MJ; Langston A; Lipscomb C; Gaylor C; Waller EK Transfusion; 2015 Oct; 55(10):2351-7. PubMed ID: 26331348 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]